BRPI0910541B8 - compostos de tetrazol - Google Patents

compostos de tetrazol

Info

Publication number
BRPI0910541B8
BRPI0910541B8 BRPI0910541A BRPI0910541A BRPI0910541B8 BR PI0910541 B8 BRPI0910541 B8 BR PI0910541B8 BR PI0910541 A BRPI0910541 A BR PI0910541A BR PI0910541 A BRPI0910541 A BR PI0910541A BR PI0910541 B8 BRPI0910541 B8 BR PI0910541B8
Authority
BR
Brazil
Prior art keywords
uric acid
ring
carbon atoms
compound
hyperuricemia
Prior art date
Application number
BRPI0910541A
Other languages
English (en)
Portuguese (pt)
Inventor
Dennen O'neil James
Arudchandran Ramachandran
Sharma Shalini
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of BRPI0910541B1 publication Critical patent/BRPI0910541B1/pt
Publication of BRPI0910541B8 publication Critical patent/BRPI0910541B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0910541A 2008-04-30 2009-04-30 compostos de tetrazol BRPI0910541B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4916708P 2008-04-30 2008-04-30
US9374308P 2008-09-03 2008-09-03
PCT/US2009/042298 WO2009134995A2 (en) 2008-04-30 2009-04-30 Tetrazole compounds for reducing uric acid

Publications (2)

Publication Number Publication Date
BRPI0910541B1 BRPI0910541B1 (pt) 2019-12-03
BRPI0910541B8 true BRPI0910541B8 (pt) 2021-05-25

Family

ID=41255799

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910541A BRPI0910541B8 (pt) 2008-04-30 2009-04-30 compostos de tetrazol

Country Status (15)

Country Link
US (2) US8410154B2 (https=)
EP (1) EP2282736B1 (https=)
JP (1) JP5431457B2 (https=)
KR (1) KR101613611B1 (https=)
CN (1) CN102014898B (https=)
AU (1) AU2009243028B2 (https=)
BR (1) BRPI0910541B8 (https=)
CA (1) CA2722624C (https=)
ES (1) ES2561039T3 (https=)
IL (1) IL209004A (https=)
MX (1) MX2010011603A (https=)
NZ (1) NZ588374A (https=)
RU (1) RU2522458C2 (https=)
WO (1) WO2009134995A2 (https=)
ZA (1) ZA201006929B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5339545B2 (ja) 2008-03-13 2013-11-13 ウェルスタット セラピューティクス コーポレイション 尿酸を減少させる化合物及び方法
MX2010011603A (es) 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Compuestos de tetrazol para reducir el acido urico.
WO2011046800A1 (en) * 2009-10-13 2011-04-21 Wellstat Therapeutics Corporation 3-substituted compounds for reducing uric acid
WO2012033720A1 (en) * 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
MY180138A (en) 2011-11-03 2020-11-23 Ardea Biosciences Inc 3,4-di-substituted pyridine compound,methods of using and compositions comprising the same
PL2775836T3 (pl) * 2011-11-04 2019-02-28 Cymabay Therapeutics, Inc. Sposoby leczenia zaostrzeń dny moczanowej
BR112014017902A2 (pt) * 2012-01-27 2017-08-22 Teijin Pharma Limited E National Univ Corporation Tottori Univ Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose
TW201443025A (zh) * 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
CN104262277B (zh) * 2014-10-07 2016-06-22 张远强 含硝基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途
CN104292177B (zh) * 2014-10-07 2016-08-17 张远强 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途
CN104292176B (zh) * 2014-10-07 2016-06-29 张远强 一种含卤代苯的四氮唑乙酸类化合物、其制备方法和用途
JP6192142B2 (ja) * 2016-09-13 2017-09-06 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 痛風発赤の治療方法
RU2683570C1 (ru) * 2018-05-23 2019-03-29 Евгений Иванович Верещагин Композиция из растительных компонентов, обладающая способностью снижать уровень мочевой кислоты сыворотки крови
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN114805233A (zh) * 2022-03-30 2022-07-29 华南理工大学 苯基四氮唑类xor抑制剂及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021556A (en) 1972-06-08 1977-05-03 Icn Pharmaceuticals, Inc. Xanthine oxidase inhibitors
US4024253A (en) 1973-04-20 1977-05-17 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Treatment of elevated histamine and uric acid levels
US4182764A (en) 1973-10-11 1980-01-08 Merck & Co., Inc. Tetrazole derivatives of [1-oxo-2-aryl or thienyl-2-substituted-5-indanyloxy(or thio)]alkanoic acids
US4874777A (en) 1987-04-10 1989-10-17 Eli Lilly And Company Leukotriene antagonists
US4845231A (en) 1988-02-12 1989-07-04 American Home Products Corporation Tetrazoles and their use as hypoglycemic agents
FR2631827B1 (fr) 1988-05-27 1992-03-27 Delalande Sa Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US5591862A (en) 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
RU2144533C1 (ru) * 1994-12-09 2000-01-20 Такеда Кемикал Индастриз, Лтд. Производные тетразола, способ их получения и фармацевтические композиции на их основе
EP0888278B1 (en) 1996-02-02 2003-07-23 Merck & Co., Inc. Antidiabetic agents
BR9814087A (pt) 1997-10-17 2000-10-03 Aventis Pharm Prod Inc Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
MXPA03011558A (es) 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US7078423B2 (en) 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
JP2004197711A (ja) * 2002-12-20 2004-07-15 Honda Motor Co Ltd 回転流体機械
EP1610812A1 (en) * 2003-03-11 2006-01-04 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
JP5339545B2 (ja) 2008-03-13 2013-11-13 ウェルスタット セラピューティクス コーポレイション 尿酸を減少させる化合物及び方法
MX2010011603A (es) 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Compuestos de tetrazol para reducir el acido urico.

Also Published As

Publication number Publication date
AU2009243028B2 (en) 2015-01-29
ZA201006929B (en) 2011-06-29
US8889724B2 (en) 2014-11-18
MX2010011603A (es) 2011-01-25
CA2722624A1 (en) 2009-11-05
US8410154B2 (en) 2013-04-02
EP2282736A4 (en) 2011-06-15
US20110206653A1 (en) 2011-08-25
EP2282736B1 (en) 2015-11-11
WO2009134995A2 (en) 2009-11-05
IL209004A0 (en) 2011-01-31
IL209004A (en) 2014-04-30
RU2522458C2 (ru) 2014-07-10
RU2010148762A (ru) 2012-06-10
ES2561039T3 (es) 2016-02-24
EP2282736A2 (en) 2011-02-16
KR101613611B1 (ko) 2016-04-19
CA2722624C (en) 2017-03-21
WO2009134995A3 (en) 2009-12-23
JP5431457B2 (ja) 2014-03-05
KR20100135851A (ko) 2010-12-27
JP2011519865A (ja) 2011-07-14
CN102014898B (zh) 2013-01-23
AU2009243028A1 (en) 2009-11-05
CN102014898A (zh) 2011-04-13
BRPI0910541B1 (pt) 2019-12-03
HK1147446A1 (en) 2011-08-12
NZ588374A (en) 2012-11-30
US20130336949A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
BRPI0910541B8 (pt) compostos de tetrazol
Yanagisawa et al. Relationship between the tautomeric structures of curcumin derivatives and their Aβ-binding activities in the context of therapies for Alzheimer's disease
ES2681794T3 (es) Uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
JP5992049B2 (ja) 置換されたキナゾリノンのための経口速放性製剤
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
Chen et al. Crystal structures of AKR1C3 containing an N-(aryl) amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer
JP2011515349A5 (https=)
BR112013014914B8 (pt) composto, composição farmacêutica e uso de um composto
MX342806B (es) Compuestos y método para reducir el ácido úrico.
BR112013003186A2 (pt) composições e métodos para tratamento de doença cardiovascular
JP2011519865A5 (https=)
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
NZ594741A (en) Specific diarylhydantoin and diarylthiohydantoin compounds
RS60697B1 (sr) Imidazo[1,2-a]piridini za lečenje ili prevenciju hiperurikemije ili gihta
EA200971026A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
HRP20151000T1 (hr) Antivirusni spojevi
UY31272A1 (es) Nuevos derivados de ácido azabifenilaminobenzoico
MA29909B1 (fr) Derives de pyridazine
WO2011011882A8 (en) Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
WO2008073451A3 (en) Benzoimidazole derivatives as sirtuin (sir) modulating compounds
BRPI0410235A (pt) inibição de pde4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento
MA33356B1 (fr) Compose anticancereux et composition pharmaceutique le contenant
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
Zou et al. Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2720 DE 23-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.